Insmed (INSM) PT Raised to $40 at BofA Securities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
UBS Starts Insmed (INSM) at Buy, 'We see ~60% upside to the current share price'
February 26, 2024 4:22 PM ESTUBS analyst Trung Huynh initiates coverage on Insmed (NASDAQ: INSM) with a Buy rating and a price target of $46.00.
The analyst comments "We are initiating on INSM with a Buy rating and $46 PT. INSM is a commercial-stage biotech developing therapies for pulmonary... More
